In line / mixed
Reported growth remained healthy, but the franchise that had driven the re-rating no longer accelerated.
[AS-EXP-030]Boston Scientific
Q4 / FY2025: Flat sequential US electrophysiology performance crystallized the share-loss fear embedded in a premium multiple.
ResultIn line / mixedGuidanceRaisedEnvironmentworsening
Investment snapshot
What happened and why it mattered
Raised
The 2026 guide left less room for the high end of consensus and increased dependence on future WATCHMAN and product-cycle recovery.
[AS-EXP-030]Acceleration
The 2026 guide left less room for the high end of consensus and increased dependence on future WATCHMAN and product-cycle recovery.
[AS-EXP-030]Qualitative
The shares de-rated because investors no longer treated the leading growth engine as competitively insulated.
[AS-ME-086]Results versus expectations
The print and the three most important read-throughs
Reported growth remained healthy, but the franchise that had driven the re-rating no longer accelerated.
- 1
Reported growth remained healthy, but the franchise that had driven the re-rating no longer accelerated.
Guidance bridge
GuidanceRaisedLatest outlook and KPI implications
The 2026 guide left less room for the high end of consensus and increased dependence on future WATCHMAN and product-cycle recovery.
| Metric | Prior | Latest | Consensus | Delta | Status | Reason / implication |
|---|---|---|---|---|---|---|
| FY reported revenue growth | FY25 actual +19.9% | 10.5%–11.5% | ~11.2% | Midpoint 11% ≈ in-line/slightly below | In line | Normalizing off elevated PFA/WATCHMAN base |
| FY operational/organic growth | LRP 10%+ CAGR | 10.0%–11.0% (organic) | ~10.9% (organic) | Midpoint 10.5%, ~40bps below | Updated | Includes ~50bps FX tailwind; brackets consensus |
| FY adjusted EPS | FY25 actual $3.06 | $3.43–$3.49 (+12–14%) | ~$3.47 | Midpoint $3.46 ≈ in-line | In line | Leveraged double-digit EPS growth; ~$0.03 FX headwind |
| FY adjusted gross margin | FY25 actual 70.6% | Roughly in line (~70.6%) | ~72%+ longer-term aspiration | Flat vs prior +30bps expansion | Updated | Favorable mix offset by supply-chain investment + tariff annualization |
| FY adjusted operating margin | LRP ~50bps/yr; FY25 +100bps | +50–75bps expansion | N/A | Below FY25's 100bps drop-through | Updated | OpEx/SG&A leverage toward 150bps LRP goal |
| FY adjusted below-the-line expense | FY25 ~$430M actual | ~$440M | N/A | Modest step-up | Updated | Higher expected interest/other |
Management signal — paraphrased
The 2026 guide left less room for the high end of consensus and increased dependence on future WATCHMAN and product-cycle recovery.
Implied cadence
The 2026 guide left less room for the high end of consensus and increased dependence on future WATCHMAN and product-cycle recovery.
Stock reaction
Why the shares moved
The shares de-rated because investors no longer treated the leading growth engine as competitively insulated.
- The shares de-rated because investors no longer treated the leading growth engine as competitively insulated.
Did the reaction persist?
[AS-ME-086]Not independently calculated in the compact record.
Adjusted-close reaction
Independent return windows were not embedded in this compact record. The reaction assessment is qualitative.
Source-reported qualitative reaction; no independent price series embeddedMarket environment delta
EnvironmentworseningWhat management said about the operating backdrop
Flat sequential US electrophysiology performance crystallized the share-loss fear embedded in a premium multiple.
- Customer demand (WATCHMAN)Mixed
No impact seen from CLOSURE/ALONE-AF/OCEAN trials; >25,000 patients treated concomitantly; robust uptake
OutlookUS WATCHMAN of $485M missed by ~2%; growth held at 29% but decelerated from Q3's 35%KPI implicationManagement interpretationMedium · Medium confidence · AS-ME-086 - Volumes / procedures (EP)Worsening
US EP flat sequentially ($606M vs $607M); EP market pegged at 18-20% Q4, not 25%
OutlookWaitlists indicate underlying demand, but growth constrained by lab capacityKPI implicationDisclosed factHigh · Medium confidence · [124] - Regional / end-marketsMixed
US +17% Q4 (+26% FY); China double-digit; Japan led by WATCHMAN/EP; EMEA +5% Q4
OutlookEMEA to accelerate in 2H26 once ACURATE annualizesKPI implicationDisclosed factMedium · Key management quotations confidence · [128]
- Channel / inventory (EMEA ERP)Improving
Back-order "mostly" reversed in Q4, providing a modest tailwind
OutlookRemoves a ~70bps drag; EMEA FY growth 3% (HSD ex-ACURATE)KPI implicationBroker/peer evidenceHigh · Medium confidence · [125] - Supply availability (Urology / AXIOS)Worsening
Urology 3.2% organic, hit by supply-chain issues and low-cost competition; AXIOS size removal for manufacturing variation, return by mid-2026
OutlookACURATE + AXIOS to cut ~150bps off Q1 2026 organic growthKPI implicationDisclosed factHigh · Medium confidence · [126] - Input costs / labor / capacityMixed
EP growth constrained by lab capacity; growth depends on ASC build-out and concomitant efficiency; continued EP/mapping hiring
Outlook2026 op-margin expansion of only 50-75bps; gross margin flatKPI implicationManagement interpretationMedium · Medium confidence · [127]
- Competition (PFA/FARAPULSE)Worsening
Anticipated losing some PFA share as new entrants launch; expects share by YE26 to roughly equal all competitors combined
OutlookUS share guided ~65%→~50% in 2026; still "clear market leader"KPI implicationManagement interpretationHigh · Medium confidence · AS-ME-086 - Pricing / VBP (China)Stable
China delivered double-digit growth led by EP, WATCHMAN, ICTx; reaffirmed sustained mid-teens over LRP
OutlookNew launches (WATCHMAN FLX Pro, FARAPULSE) offset VBP price pressureKPI implicationDisclosed factMedium · Medium confidence · [123]
Evidence and confidence
Source map
No material gap recorded.
AlphaSense synthesis
Open source ↗Official company source
Open source ↗AlphaSense market-environment synthesis
Open source ↗